Search

This Thursday is the next-to-last day of COP26 and the association believes it is important to remember that biotechnology can cut greenhouse-gas emissions up to 65% and has a direct impact on 11 of

The President of Navarra, María Chivite, has described this sector as strategic for economic recovery and with great potential for job creation. This international benchmark event, organised by AseBio

The Regional Minister for Economic and Business Development, Mikel Irujo, underlines Navarre's leadership and highlights the importance of BIOSPAIN in promoting relations between Navarrese companies

Biotech companies are expanding their workforce amid the pandemic, accentuating in 2020 the growth trend of recent years, in which staff increased by 7.6% in 2019 and accounted for 12.8% of people

The pandemic has provided an opportunity for Spanish biotechnology and private investment has increased by 50% in 2020. BIOSPAIN 2021, the reference Spanish trade fair for investment agents and

Most of these companies will be at the most important annual event for the sector, BIOSPAIN 2021, which will be held in Pamplona-Iruña from 27th September to 1rst October

Biotech companies launched 70% more products and services to market and Spain moved to eighth in the world in scientific production in biotechnology

Precision medicine and personalised medicine products or services have gone from representing 12% of total launches to 52% in 2020. Navarra, which is hosting Biospain 2021, is one of the pioneering

This year saw over €150 million in private capital invested, compared to €103 million in 2019. Publicly traded biotech firms attracted over €70 million on capital markets, up 35% from 2019

BIOSPAIN will be held at the Palacio de Congresos y Auditorio de Navarra-Baluarte in Pamplona, from 27 September to 1 October 2021, following a hybrid format

Spain is positioned as a leader and benchmark country in advanced therapies, the cornerstone for the treatment of diseases such as cancer, where 62% of clinical trials are conducted.

Photonics is an industry that has aroused Merck's curiosity for more than 30 years

Merck is accelerating development and production, and bringing resources and expertise to help identify effective and scalable solutions to the pandemic of Covid-19

Innovation present in Oryzon's programs in the field of epigenetics acknowledged. The company currently has 2 compounds in Phase II clinical studies, iadademstat and vafidemstat

This article will focus on the Systematic Scientific Literature Search and Review as part of the Clinical Evaluation process

This collaboration responds to the high quality of the research and scientific talent of the Hospital Nacional de Parapléjicos and the commitment of the science and technology company Merck to invest

Mirum expands potential opportunities across rare disease pipeline and Vivet will lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2

Biotech company OWL Metabolomics develops non-invasive, early diagnosis products for obesity-related diseases

Goal is to explore effects of LSD1 inhibition on animal models of autism in Shank3 deficient mice models

In 2020, biologist Gema Malet Engra joined the biotechnology company Laminar Pharmaceuticals after a successful 15-year career in fundamental and applied research in Oncology at several international

PORTICO is a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder recruiting patients in Europe and the U.S and dedicated to independent assessment of reduction of agitation